AstraZeneca Signs Letter of Intent with IDT Biologika to Boost COVID-19 Vaccine Manufacturing Capability in the EU

 AstraZeneca Signs Letter of Intent with IDT Biologika to Boost COVID-19 Vaccine Manufacturing Capability in the EU

AstraZeneca’s COVID-19 Vaccine Demonstrates 92% Efficacy Against Delta (Indian) Variant

Shots:

  • AstraZeneca and IDT Biologika are exploring options to accelerate output of finished AZ’s COVID-19 vaccine in Q2’21 to support EU’s immediate vaccination needs during the pandemic
  • The companies plan to strengthen EU’s vaccine manufacturing capability as they plan to invest in capacity expansion at IDT Biologika’s production site iGermany to build up to five 2,000-litre bioreactors capable of making 10M of doses/mos. The new assets anticipated to be operational by the end of 2022
  • Following the EMA’s approval, millions of AstraZeneca vaccines began shipping on Feb 05, 2021 as part of the initial 17M doses that are due to be delivered over the next weeks, with more planned in Mar’2021

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Business Standard

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post